Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance
Drug Safety · 2024-11 · 47 (11) · 1127-1136
DOI: 10.1007/s40264-024-01448-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Safety, online erschienen am 19.06.2024. Verfasst von Cosimo Zaccaria und 4 weiteren Autor:innen. Beteiligte Einrichtung: European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS, Amsterdam, The Netherlands. Cosimo.Zaccaria@ema.europa.eu. Hauptthemen laut MEDLINE: Pharmacovigilance, Algorithms, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
INTRODUCTION: There is a need to strengthen the evidence base regarding medication use during pregnancy and to facilitate the early detection of safety signals. EudraVigilance (EV) serves as the primary system for managing and analysing information concerning suspected adverse drug reactions (ADRs) within the European Economic Area. Despite its various functionalities, the current format for electronic submissions of safety reports lacks a specific data element indicating medicine exposure during pregnancy. OBJECTIVE: This paper aims to address the limitations of existing approaches by developing a rule-based algorithm in EV that more reliably identifies cases that are truly representative of an ADR during pregnancy. METHODS: The study utilised the standardised MedDRA query (SMQ) 'Pregnancy and neonatal topics' (PNT) as a benchmark for comparison. Recognising that the SMQ PNT also retrieves healthy pregnancy outcomes, contraceptive failure, failed abortifacients as well as ADRs not associated with pregnancy, a novel algorithm was tailored to improve the accuracy of identifying suspected ADRs occurring during pregnancy. RESULTS: Upon testing, the algorithm demonstrated superior performance, correctly predicting 90% of cases reporting an ADR during pregnancy, compared to 54% achieved by the SMQ PNT. The implementation of the algorithm in EV led to the retrieval of 202,426 cases. CONCLUSION: The development and successful testing of the novel algorithm represents a step forward in pregnancy-specific signal detection in EV. Because signals associated with pregnancy may be diluted in a large database such as EV, this study lays the groundwork for future research to evaluate the effectiveness of disproportionality methods on a more refined subset of pregnancy-related ADR reports.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS, Amsterdam, The Netherlands. Cosimo.Zaccaria@ema.europa.eu.
- European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS, Amsterdam, The Netherlands.
- Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, UK.
Zitieren
APA
Zaccaria, C., Piccolo, L., Gordillo-Marañón, M., Touraille, G., & de Vries, C. (2024). Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance. Drug Safety, 47(11), 1127-1136. https://doi.org/10.1007/s40264-024-01448-y
Vancouver
Zaccaria C, Piccolo L, Gordillo-Marañón M, Touraille G, de Vries C. Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance. Drug Safety. 2024;47(11):1127-1136. doi:10.1007/s40264-024-01448-y
BibTeX
@article{Zaccaria2024,
author = {Zaccaria, Cosimo and Piccolo, Loris and Gordillo-Marañón, María and Touraille, Gilles and de Vries, Corinne},
title = {Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance},
journal = {Drug Safety},
year = {2024},
volume = {47},
number = {11},
pages = {1127--1136},
doi = {10.1007/s40264-024-01448-y}
}
EUVIMED